Dysregulation of the autonomic nervous system predicts the development of the metabolic syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2484-2493

  Licht, Carmilla M M ^a   De Geus, Eco J C ^a,b   Penninx, Brenda W J H ^a,c,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; CARDIAC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HEART PREEJECTION PERIOD; HEART RATE; HUMAN; LIPID METABOLISM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NETHERLANDS; PARASYMPATHETIC TONE; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY SINUS ARRHYTHMIA; SINUS ARRHYTHMIA; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CHOLESTEROL, HDL; FEMALE; HEART; HEART RATE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 84878508681     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3104     Document Type: Article

References (95)

1. Chandola T, Brunner E, Marmot M. Chronic stress at work and the metabolic syndrome: prospective study. BMJ. 2006;332(7540):521-525.
2. Hjemdahl P. Stress and the metabolic syndrome: an interesting but enigmatic association. Circulation. 2002;106(21):2634-2636. (Pubitemid 35364912)
3. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology. 2005;30(1):1-10. (Pubitemid 39195039)
4. Bruinstroop E, Pei L, Ackermans MT, et al. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes. 2012;61(5):1043-1050.
5. Kalsbeek A, Bruinstroop E, Yi CX, Klieverik LP, La Fleur SE, Fliers E. Hypothalamic control of energy metabolism via the autonomic nervous system. Ann NY Acad Sci. 2010;1212:114-129.
6. Palatini P, Longo D, Zaetta V, Perkovic D, Garbelotto R, Pessina AC. Evolution of blood pressure and cholesterol in stage 1 hypertension: role of autonomic nervous system activity. J Hypertens. 2006;24(7):1375-1381. (Pubitemid 43948337)
7. Stein PK, Barzilay JI, Chaves PH, et al. Higher levels of inflammation factors and greater insulin resistance are independently associated with higher heart rate and lower heart rate variability in normoglycemic older individuals: the Cardiovascular Health Study. J Am Geriatr Soc. 2008;56(2):315-321. (Pubitemid 351160704)
8. Straznicky NE, Eikelis N, Nestel PJ, et al. Baseline sympathetic nervous system activity predicts dietary weight loss in obese metabolic syndrome subjects. J Clin Endocrinol Metab. 2012;97(2):605-613.
9. Licht CM, Vreeburg SA, van Reedt Dortland AK, et al. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin Endocrinol Metab. 2010;95(5):2458-2466.
10. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403-414. (Pubitemid 46135879)
11. Guize L, Pannier B, Thomas F, Bean K, Jégo B, Benetos A. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis. 2008;101(9):577-583.
12. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;31(9):1898-1904.
13. Tentolouris N, Argyrakopoulou G, Katsilambros N. Perturbed autonomic nervous system function in metabolic syndrome. Neuromolecular Med. 2008;10(3):169-178.
14. Brunner EJ, Hemingway H, Walker BR, et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation. 2002;106(21):2659-2665. (Pubitemid 35364919)
15. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension. 2004;44(6):847-852. (Pubitemid 39577410)
16. Grassi G, Quarti-Trevano F, Seravalle G, Dell'Oro R, Dubini A, Mancia G. Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome. Metabolism. 2009;58(10):1446-1451.
17. Koskinen T, Kähönen M, Jula A, et al. Metabolic syndrome and short-term heart rate variability in young adults. The cardiovascular risk in young Finns study. Diabet Med. 2009;26(4):354-361.
18. Liao D, Sloan RP, Cascio WE, et al. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care. 1998;21(12):2116-2122. (Pubitemid 28549160)
19. Min KB, Min JY, Paek D, Cho SI. The impact of the components of metabolic syndrome on heart rate variability: using the NCEP-ATP III and IDF definitions. Pacing Clin Electrophysiol. 2008;31(5):584-591. (Pubitemid 351595288)
20. Soares-Miranda L, Sandercock G, Vale S, et al. Metabolic syndrome, physical activity and cardiac autonomic function. Diabetes Metab Res Rev. 2012;28(4):363-369.
21. Puttonen S, Härmä M, Hublin C. Shift work and cardiovascular disease - pathways from circadian stress to morbidity. Scand J Work Environ Health. 2010;36(2):96-108.
22. Penninx BWJH, Beekman ATF, Smit JH, et al. The Netherlands Study of Depression and Anxiety (NESDA): Rationale, Objectives and Methods. Int J Meth Psychiatr Res. 2008;17(3):121-140.
23. Lamers F, Hoogendoorn AW, Smit JH, et al. Sociodemographic and psychiatric determinants of attrition in the Netherlands Study of Depression and Anxiety (NESDA). Compr Psychiatry. 2012;53(1):63-70.
24. Licht CM, de Geus EJ, van Dyck R, Penninx BW. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry. 2010;68(9):861-868.
25. van Reedt Dortland AKB, Giltay EJ, van Veen T, Zitman FG, Penninx BWJH. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand. 2010;122:30-39.
26. Kveiborg B, Christiansen B, Major-Petersen A, Torp-Pedersen C. Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol. Am J Cardiovasc Drugs. 2006;6(4):209-217. (Pubitemid 44285130)
27. Ladage D, Reidenbach C, Rieckeheer E, Graf C, Schwinger RH, Brixius K. Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age. J Cardiovasc Pharmacol. 2010;56(3):275-281.
28. Lee P, Kengne AP, Greenfield JR, Day RO, Chalmers J, Ho KK. Metabolic sequelae of beta-blocker therapy: weighing in on the obesity epidemic? Int J Obes (Lond). 2011;35(11):1395-1403.
29. Lurje L, Wennerblom B, Tygesen H, Karlsson T, Hjalmarson A. Heart rate variability after acute myocardial infarction in patients treated with atenolol and metoprolol. Int J Cardiol. 1997;60(2):157-164. (Pubitemid 27304379)
30. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13. (Pubitemid 36835815)
31. Willenheimer R, van Veldhuisen DJ, Ponikowski P, Lechat P. Beta-blocker treatment before angiotensin-converting enzyme inhibitor therapy in newly diagnosed heart failure. J Am Coll Cardiol. 2005;46(1):182. (Pubitemid 40905152)
32. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2752. (Pubitemid 41532612)
33. Palatini P. Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J. 2005;26(10):943-945. (Pubitemid 40695020)
34. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care. 2012;30(suppl 1):S4 -S41.
35. Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21(4):641-648. (Pubitemid 28172949)
36. Goa KL, Barradell LB, Plosker GL. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs. 1996;52(5):725-753. (Pubitemid 26382190)
37. Goldbourt U, Brunner D, Behar S, Reicher-Reiss H. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J. 1998; 19(suppl H):H42-H47. (Pubitemid 28321424)
38. Packard CJ. Overview of fenofibrate. Eur Heart J. 1998;19(suppl A):A62-A65. (Pubitemid 28112480)
39. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410-418. (Pubitemid 29362514)
40. Spencer CM, Barradell LB. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs. 1996;51(6):982-1018.
41. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85(9):1100-1105. (Pubitemid 30214256)
42. Grundy SM. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol. 2002;90(8A):11i-21i. (Pubitemid 35284907)
43. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47(9):1097-1104. (Pubitemid 28428015)
44. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan). Int J Clin Pract. 2007;61(11):1914-1921. (Pubitemid 47573088)
45. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vasc Health Risk Manag. 2007;3(4):467-479. (Pubitemid 47542608)
46. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-3264.
47. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens. 2004;22(3):435-445. (Pubitemid 38368472)
48. Tannen RL, Weiner MG, Marcus SM. Simulation of the Syst-Eur randomized control trial using a primary care electronic medical record was feasible. J Clin Epidemiol. 2006;59(3):254-264.
49. de Geus EJ, Willemsen GH, Klaver CH, van Doornen LJ. Ambulatory measurement of respiratory sinus arrhythmia and respiration rate. Biol Psychol. 1995;41(3):205-227.
50. Willemsen GH, De Geus EJ, Klaver CH, Van Doornen LJ, Carroll D. Ambulatory monitoring of the impedance cardiogram. Psychophysiology. 1996;33(2):184-193. (Pubitemid 26076328)
51. Sherwood A, Allen MT, Fahrenberg J, Kelsey RM, Lovallo WR, van Doornen LJ. Methodological guidelines for impedance cardiography. Psychophysiology. 1990;27(1):1-23. (Pubitemid 20169855)
52. Berntson GG, Norman GJ, Hawkley LC, Cacioppo JT. Cardiac autonomic balance versus cardiac regulatory capacity. Psychophysiology. 2008;45(4):643-652. (Pubitemid 351832083)
53. Grossman P, Kollai M. Respiratory sinus arrhythmia, cardiac vagal tone, and respiration: within- and between-individual relations. Psychophysiology. 1993;30(5):486-495. (Pubitemid 23250122)
54. Ritz T, Dahme B. Implementation and interpretation of respiratory sinus arrhythmia measures in psychosomatic medicine: practice against better evidence? Psychosom Med. 2006;68(4):617-627. (Pubitemid 44297660)
55. Tsuji H, Larson MG, Venditti FJ Jr, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996;94(11):2850-2855. (Pubitemid 26411751)
56. Grossman P, Karemaker J, Wieling W. Prediction of tonic parasympathetic cardiac control using respiratory sinus arrhythmia: the need for respiratory control. Psychophysiology. 1991;28(2):201-216.
57. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7(5):335-346.
58. Judy WV, Watanabe AM, Henry DP, Besch HR Jr, Murphy WR, Hockel GM. Sympathetic nerve activity: role in regulation of blood pressure in the spontaenously hypertensive rat. Circ Res. 1976;38(6 suppl 2):21-29.
59. Ayad F, Belhadj M, Pariés J, Attali JR, Valensi P. Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications. Diabet Med. 2010;27(7):804-811.
60. Singh JP, Larson MG, Tsuji H, Evans JC, O'Donnell CJ, Levy D. Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. Hypertension. 1998;32(2):293-297. (Pubitemid 28376487)
61. Valensi P, Doaré L, Perret G, Germack R, Pariès J, Mesangeau D. Cardiovascular vagosympathetic activity in rats with ventromedial hypothalamic obesity. Obes Res. 2003;11(1):54-64. (Pubitemid 41137539)
62. Assoumou HG, Pichot V, Barthelemy JC, et al. Metabolic syndrome and short-term and long-term heart rate variability in elderly free of clinical cardiovascular disease: the PROOF study. Rejuvenation Res. 2010;13(6):653-663.
63. Burker EJ, Fredrikson M, Rifai N, Siegel W, Blumenthal JA. Serum lipids, neuroendocrine, and cardiovascular responses to stress in men and women with mild hypertension. Behav Med. 1994;19(4):155-161. (Pubitemid 24127749)
64. Grynberg A, Ziegler D, Rupp H. Sympathoadrenergic overactivity and lipid metabolism. Cardiovasc Drugs Ther. 1996;10(suppl 1):223-230. (Pubitemid 26191027)
65. Lee ZS, Critchley JA, Tomlinson B, et al. Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese. Metabolism. 2001;50(2):135-143. (Pubitemid 32170823)
66. Nash DT. Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism. Clin Cardiol. 1990;13(11):764-772.
67. Ward KD, Sparrow D, Landsberg L, Young JB, Vokonas PS, Weiss ST. The relationship of epinephrine excretion to serum lipid levels: the Normative Aging Study. Metabolism. 1994;43(4):509-513. (Pubitemid 24113175)
68. Grøntved A, Steene-Johannessen J, Kynde I, et al. Association between plasma leptin and blood pressure in two population-based samples of children and adolescents. J Hypertens. 2011;29(6):1093-1100.
69. Millet L, Barbe P, Lafontan M, Berlan M, Galitzky J. Catecholamine effects on lipolysis and blood flow in human abdominal and femoral adipose tissue. J Appl Physiol. 1998;85(1):181-188. (Pubitemid 28334923)
70. Pikkujämsä SM, Huikuri HV, Airaksinen KE, et al. Heart rate variability and baroreflex sensitivity in hypertensive subjects with and without metabolic features of insulin resistance syndrome. Am J Hypertens. 1998;11(5):523-531. (Pubitemid 28270712)
71. Rayner DV, Trayhurn P. Regulation of leptin production: sympathetic nervous system interactions. J Mol Med (Berl). 2001;79(1):8-20. (Pubitemid 32250019)
72. Straznicky NE, Lambert GW, McGrane MT, et al. Weight loss may reverse blunted sympathetic neural responsiveness to glucose ingestion in obese subjects with metabolic syndrome. Diabetes. 2009;58(5):1126-1132.
73. Troisi RJ, Weiss ST, Parker DR, et al. Relation of obesity and diet to sympathetic nervous system activity. Hypertension. 1991;17(5):669-677.
74. Horio T, Miyazato J, Kamide K, Takiuchi S, Kawano Y. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens. 2003;16(11 pt 1):938-944. (Pubitemid 37315493)
75. Miao DM, Ye P, Xiao WK, Gao P, Zhang JY, Wu HM. Influence of low high-density lipoprotein cholesterol on arterial stiffening and left ventricular diastolic dysfunction in essential hypertension. J Clin Hypertens (Greenwich). 2011;13(10):710-715.
76. Schillaci G, Vaudo G, Reboldi G, et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens. 2001;19(12):2265-2270. (Pubitemid 33135250)
77. Zhang X, Zhang K. Endoplasmic reticulum stress-associated lipid droplet formation and type ii diabetes. Biochem Res Int. 2012;2012:247275.
78. Sheffield D, Krittayaphong R, Cascio WE, et al. Heart rate variability at rest and during mental stress in patients with coronary artery disease: differences in patients with high and low depression scores. Int J Behav Med. 1998;5(1):31-47. (Pubitemid 28328045)
79. Hughes JW, Stoney CM. Depressed mood is related to high-frequency heart rate variability during stressors. Psychosom Med. 2000;62(6):796-803. (Pubitemid 32009086)
80. Gianaros PJ, Salomon K, Zhou F, et al. A greater reduction in high-frequency heart rate variability to a psychological stressor is associated with subclinical coronary and aortic calcification in postmenopausal women. Psychosom Med. 2005;67(4):553-560. (Pubitemid 41033583)
81. Berntson GG, Cacioppo JT, Quigley KS. Respiratory sinus arrhythmia: autonomic origins, physiological mechanisms, and psychophysiological implications. Psychophysiology. 1993;30(2):183-196. (Pubitemid 23049784)
82. Vrijkotte TG, van Doornen LJ, de Geus EJ. Overcommitment to work is associated with changes in cardiac sympathetic regulation. Psychosom Med. 2004;66(5):656-663.
83. van Lien R, Goedhart A, Kupper N, Boomsma D, Willemsen G, de Geus EJ. Underestimation of cardiac vagal control in regular exercisers by 24-hour heart rate variability recordings. Int J Psychophysiol. 2011;81(3):169-176.
84. Brunham LR, Kruit JK, Hayden MR, Verchere CB. Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes. Curr Diab Rep. 2010;10(1):55-60.
85. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther. 2006;111(3):893-908. (Pubitemid 44164383)
86. Lim S, Park YM, Sakuma I, Koh KK. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol [published online April 12, 2012]. Int J Cardiol. doi:10.1016/j.ijcard.2012.03.127.
87. Pontiroli AE, Monti LD, Pizzini A, Piatti P. Familial clustering of arterial blood pressure, HDL cholesterol, and pro-insulin but not of insulin resistance and microalbuminuria in siblings of patients with type 2 diabetes. Diabetes Care. 2000;23(9):1359-1364.
88. Prince CT, Secrest AM, Mackey RH, Arena VC, Kingsley LA, Orchard TJ. Pulse wave analysis and prevalent cardiovascular disease in type 1 diabetes. Atherosclerosis. 2010;213(2):469-474.
89. Akutsu Y, Kaneko K, Kodama Y, et al. The significance of cardiac sympathetic nervous system abnormality in the long-term prognosis of patients with a history of ventricular tachyarrhythmia. J Nucl Med. 2009;50(1):61-67.
90. Akutsu Y, Kaneko K, Kodama Y, et al. Significance of cardiac sympathetic nervous system abnormality for predicting vascular events in patients with idiopathic paroxysmal atrial fibrillation. Eur J Nucl Med Mol Imaging. 2010;37(4):742-749.
91. Bigger JT Jr, Fleiss JL, Rolnitzky LM, Steinman RC. Frequency domain measures of heart period variability to assess risk late after myocardial infarction. J Am Coll Cardiol. 1993;21(3):729-736. (Pubitemid 23076291)
92. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation. 2001;104(17):2024- 2028. (Pubitemid 33027041)
93. Dekker JM, Crow RS, Folsom AR, et al. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC Study. Atherosclerosis Risk In Communities. Circulation. 2000;102(11):1239-1244.
94. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109(5):685-692.
95. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 1997;15(1):3-17. (Pubitemid 27075981)